I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING FILED VIA THE

(b)

 \boxtimes

	ELECTRO	NIC FILING SYSTEM, OF	N:						
		Mai	rch 21, 20	008					
	/Anita J. G			March 21, 2008					
SIGNATURE DATE IN THE UNITED STATES PATENT AND TRADEMARK OFFICE									
Applio	cants		:	Zee Upton et al.					
Serial No.			:	10/565,616					
Filing Date			:	June 9, 2006					
For			:	SKIN REGENERATION SYSTEM					
Art Unit			:	1636					
Confirmation No.			:	2998					
Examiner			:	TBD					
Attorr	Attorney Docket		:	FAK-8011					
Comr P.O. I	Stop Amenomissioner fo Box 1450 Indria, VA								
		INFORMATION I	DISCLO	SURE STATEMENT					
Sir:									
1.	Pursuant to 37 CFR §1.97 and §1.98, and in compliance with CFR §1.56, the Office's attention is directed to the patents, pending applications, publications and other information listed on the attached PTO-1449. Applicant(s) make no admission that the documents are prior art to the present invention.								
2.	Regarding each listed document that is not in the English language, an English-language translation accompanies this Statement as indicated on the attached PTO-1449 or a corresponding U.S. Patent is enclosed, or an English abstract, or a concise explanation of the relevance of the document is set forth on an attached sheet.								
3.	Pursuant checked):		this State	ement is being filed (one must be					
	(a) 🗌	Within three mor							

Before the mailing date of a first Office

Action on the merits.

	(c)		After the period set forth in 37 CFR §1.97(b) but before the mailing date of either a final action or a notice of allowance or an action that otherwise closes prosecution in the application.					
			1)		A certification is given below,			
			2)		Enclosed is a check covering the fee (\$180.00) set forth in §1.17(p) for consideration of this Statement, or			
			3)		Charge the fee set forth in 37 CFR §1.17(p) to Deposit Account No. 20-0090.			
	(d)		After the mailing date of either a final action or a notice of allowance, but before payment of the issue fee. The required certification and fee is indicated below.					
			1)		Enclosed is a check covering the fee set forth in 37 CFR §1.17(p) \$180, or			
			2)		Charge the fee set forth in 37 CFR §1.17(p) to Deposit Account No. 20-0090.			
4.	Certification (if applicable):							
	(a)		The undersigned hereby certifies that each item of information contained in this Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.					
	(b)		The undersigned hereby certifies that no item of information contained in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the undersigned's knowledge after making reasonable inquiry no item of information contained in the Statement, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Statement.					
5.	The Commissioner is hereby authorized to charge any additional fees,							

fees underpaid, or credit any overpayment with regard to this

Statement to Deposit Account No. 20-0090.

6.	Concise	Explanation	/if	needed	١٠

 Below is a Concise Statement of Relevance of enclosed non-English language document(s).

OTHER DOCUMENTS

Schleicher et al., "Surface Modification by Complexes of Vitronectin and Growth Factors for Serum-Free Culture of Human Osteoblasts", *Tissue Engineering*, Vol. 11, No. 11-12, November 2005, pos. 1688-1698, XP-009072079.

Kricker et al., "Structural and Functional Evidence for the Interaction of Insulin-Like Growth Factors (IGFs) and IGF Binding Proteins with Vitronectin", Endocrinology, Vol. 144, No. 7, July 2003, pas. 2807-2815, XP-002398183.

Grant et al., "The Co-Application of Sprayed Cultured Autologous Keratinocytes and Autologous Fibrin Sealant in a Porcine Wound Model", *British Journal of Plastic Surgery*, Vol. 55, No. 3, April 2002, pages 219-227, XP-002398188

Nam et al., "Vitronectin Binding to IGF Binding Protein-5 (IGFBP-5) Alters IGFBP-5 Modulation of IGF-I Actions", *Endorinology*, Vol. 143, No. 1, January 2002, pgs. 30-36.

Respectfully submitted,

/Richard S. Wesorick/

Richard S. Wesorick Reg. No. 40,871

TAROLLI, SUNDHEIM, COVELL, & TUMMINO L.L.P. 1300 East Ninth Street, Suite 1700 Cleveland, OH 44114 Phone: (216) 621-2234

Fax: (216) 621-4072 Customer No.: 26,294